GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
Parkinson’s disease
Posted inNeuroscience, New Drugs, Regulatory
Oligomannate: Finally New Drug to Treat Alzheimer’s Disease
Innovative Chinese medicine eliminates gut microbiota dysbiosis, and it helps slow the progression of dementia in Alzheimer’s disease.
Posted inClinical Trials, In the Pipeline, Neuroscience
Treating Parkinson’s Disease: Betting on Alpha-Synuclein
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.
Posted inClinical Trials, Neuroscience
Buntanetap: Breakthrough in Treatment of Alzheimer’s and Parkinson’s
Buntanetap acts simultaneously on three neurotoxic proteins responsible for neurodegenerative disorders: amyloid beta, alpha-synuclein, and tau protein.